2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Workforce, Adverse Events, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Hemophilia, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Paroxysmal Nocturnal Hemoglobinuria, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Metabolic Disorders, Iron Deficiency, Iron Overload, B Cell Lymphoma, Research, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4381 Safety and efficacy of transfusional iron overload screening and treatment in children and young adults following anti-neoplastic therapy or hematopoietic stem cell transplantation

Rhea Singh, Melissa Acquazzino, MD2, Michelle Brenner, DO, MS3, Mahua Dasgupta, PhD4, Rachel Phelan, MD, MPH5, Nathan Schloemer, MD6, Debra Schmidt, APNP7, Ke Yan, PhD, MS8, Allison Remiker, MD9
1 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
2 University of Nebraska, Lincoln, Nebraska, United States
3 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
4 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
5 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
6 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
7 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
8 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
9 Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Introduction: Transfusional iron overload (TIO) is a known complication of repeated packed red blood cell (pRBC) transfusions, which are often required in the treatment of patients undergoing oncologic treatment or hematopoietic cell transplantation (HCT). However, there is limited data and standardization for screening and treatment specifically for these diagnoses. This study describes the outcomes of pediatric and young adult oncology and HCT patients evaluated and treated using a standardized institutional algorithm for TIO. 

Methods: The medical records of children and young adults (0-25 years) with oncologic diagnoses or HCT who developed TIO were retrospectively reviewed at a single tertiary pediatric center (Children’s Wisconsin) between November 3, 2012, and December 31, 2024. Per the institutional algorithm, patients were screened with serum ferritin based on diagnosis: 1 year post-transfusion independence or 1 year from starting maintenance chemotherapy for hematologic malignancies, and 1 year after treatment completion for non-hematologic malignancies. Demographic characteristics, diagnoses, transfusion history, laboratory studies, treatment details, liver and cardiac MRI findings, and treatment outcomes were collected. Descriptive statistics, Spearman’s correlation coefficient, and regression analyses were used to evaluate the data.

Results: The cohort included 157 patients. The mean age was 10 years, and 69 (44%) were female. Primary diagnoses included 84 blood cancers (53.5%), 16 CNS malignancies (10.2%), 47 solid tumors (29.9%), and 10 bone marrow failure syndromes (6.4%). Patients received a median of 18 (IQR 12-27) pRBC transfusions. Of the 157 patients, 56 (35.7%) underwent therapeutic phlebotomy only, 4 (2.5%) received iron chelation therapy only, and 3 (1.9%) received both treatments.  

Patients undergoing phlebotomy completed a median of 8 sessions (IQR 6-12) occurring over a median period of 0.6 years (IQR 0.4-1.2). Phlebotomy complications occurred in 4 patients (6.8%) (lightheadedness, dizziness, and soreness). Prior to treatment, the median liver iron concentration (LIC) was 7.3 mg/g dry weight (IQR 5.2-9.3) and median ferritin was 1175 ng/mL (IQR 758-1970). Eighteen patients (28.6%) being treated for iron overload received a cardiac MRI; however, findings were not analyzed due to the small sample size. After treatment, LIC was reduced by a median of 3.4 mg/g dry weight (IQR 2.6-4.7), and ferritin was reduced by a median of 720.4 ng/mL (IQR 375-1554). The number of pRBC transfusions was positively correlated with the number of phlebotomy sessions administered (R2=0.52, p<0.0001).

Conclusions: Among pediatric and young adult oncology and HCT patients identified through a standardized institutional screening algorithm, therapeutic phlebotomy was associated with meaningful reductions in liver iron concentration and ferritin, and few documented adverse events. Higher transfusion burden was associated with an increased number of phlebotomy sessions, suggesting that patients with greater cumulative transfusional exposure may require more intensive iron reduction therapy.

Rhea Singh: No relevant conflicts of interest to declare.